<DOC>
	<DOCNO>NCT00274300</DOCNO>
	<brief_summary>The purpose study evaluate well vaccine tolerate site administration give effect may subject ' wellbeing . The study also test ability vaccine cause particular immune response body evaluate effect herpes outbreaks</brief_summary>
	<brief_title>Safety Study HSV2 DNA Vaccine Treat Patients With Recurrent Genital Herpes Caused HSV-2</brief_title>
	<detailed_description>Herpes simplex virus type 2 ( HSV-2 ) infection serious public health problem , 20 % US population infect . Following primary infection , HSV-2 establish latent infection lead recurrent disease virus reactivate . Genital lesion often experience viral recurrence uncomfortable painful , result significant anxiety social distress . There commercial vaccine available therapy HSV-2 infection.The aim therapeutic vaccine would enhance natural response boost appropriate cellular immune response HSV-2 latently infect individual experience frequent unwanted reactivations . The purpose study evaluate safety tolerability profile pPJV7630 HSV-2 DNA vaccine administer Particle Mediated Epidermal Delivery ( PMED )</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Otherwise healthy subject recurrent genital herpes due HSV2 infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>DNA vaccine</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>Herpes Simplex Virus Type 2 ( HSV2 )</keyword>
	<keyword>Particle Mediated Epidermal Delivery</keyword>
</DOC>